Relmada Therapeutics (RLMD) Return on Capital Employed Growth (3y) (2017 - 2026)

Relmada Therapeutics (RLMD) Return on Capital Employed Growth (3y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 4,893.00
4 NuCana 279.75 Bn 279.75 Bn - 2,416.00
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -494.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -649.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -3,782.00
10 Relmada Therapeutics 205.29 Mn 205.29 Mn - 7,289.00

Historic Data

Download Data
DateValue
Mar 31, 2026 7,289.00
Dec 31, 2025 -2,075.00
Sep 30, 2025 -36,491.00
Jun 30, 2025 -28,653.00
Mar 31, 2025 -18,334.00
Dec 31, 2024 -11,876.00
Sep 30, 2024 -2,963.00
Jun 30, 2024 -4,083.00
Mar 31, 2024 -5,080.00
Dec 31, 2023 -5,810.00
Sep 30, 2023 -6,981.00
Jun 30, 2023 -7,758.00
Mar 31, 2023 -8,140.00
Dec 31, 2022 -5,614.00
Jun 30, 2022 32,590.00
Mar 31, 2022 128,868.00
Dec 31, 2021 166,858.00
Sep 30, 2021 -29,022.00
Mar 31, 2021 446,087.00
Dec 31, 2020 37,252.00